Modified PENG Plus Suprascapular Nerve Block Versus Interscalene Block for Bankart and Latarjet Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCairo University

About this trial

This randomized controlled trial aims to compare the analgesic efficacy and safety of a Modified Pericapsular Nerve Group (PENG) Block combined with Suprascapular Nerve Block (SSNB) versus Interscalene Brachial Plexus Block (ISB) in adult patients undergoing elective Bankart repair or Latarjet surgery under general anesthesia. Seventy patients will be randomized to receive either Modified PENG plus SSNB or ISB. The primary outcome is postoperative pain intensity measured by the Visual Analog Scale (VAS) at 24 hours. Secondary outcomes include opioid consumption, time to first rescue analgesia, functional recovery, range of motion, and block-related complications including respiratory compromise, motor weakness, Horner syndrome, hoarseness, and local anesthetic systemic toxicity. This randomized controlled trial aims to compare the analgesic efficacy and safety of a Modified Pericapsular Nerve Group (PENG) Block combined with Suprascapular Nerve Block (SSNB) versus Interscalene Brachial Plexus Block (ISB) in adult patients undergoing elective Bankart repair or Latarjet surgery under general anesthesia. Seventy patients will be randomized to receive either Modified PENG plus SSNB or ISB. The primary outcome is postoperative pain intensity measured by the Visual Analog Scale (VAS) at 24 hours. Secondary outcomes include opioid consumption, time to first rescue analgesia, functional recovery, range of motion, and block-related complications including respiratory compromise, motor weakness, Horner syndrome, hoarseness, and local anesthetic systemic toxicity.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

• Male or female patients aged 18 to 65 years.

Patients undergoing elective Bankart repair or Latarjet surgery.

American Society of Anesthesiologists (ASA) physical status I or II.

History of allergy to local anesthetics.

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • • Modified PENG Block combined with Suprascapular Nerve Block

    Procedure/Surgery

    Ultrasound-guided Modified Pericapsular Nerve Group (PENG) Block combined with Suprascapular Nerve Block (SSNB) performed before induction of general anesthesia. The Modified PENG Block is performed with 20 mL of 0.25% bupivacaine and the SSNB with 10 mL of 0.25% bupivacaine for postoperative analgesia in patients undergoing elective Bankart repair or Latarjet surgery

  • • Interscalene Brachial Plexus Block

    Procedure/Surgery

    Ultrasound-guided Interscalene Brachial Plexus Block performed before induction of general anesthesia using 20 mL of 0.25% bupivacaine for postoperative analgesia in patients undergoing elective Bankart repair or Latarjet surgery

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Modified PENG + Suprascapular Nerve Block (SSNB)Experimental treatment 1 intervention
Group B: Interscalene Brachial Plexus Block (ISB)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analog Scale (VAS) Pain Score at Rest at 24 Hours Postoperatively

Pain intensity at rest will be assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain), 24 hours after surgery. Higher scores indicate worse pain. The primary comparison is between the Modified PENG Block combined with Suprascapular Nerve Block and the Interscalene Brachial Plexus Block.

Time frame
24 hours after surgery

Secondary outcomes

1

Visual Analog Scale (VAS) Pain Scores at Postoperative Time Points

Pain intensity will be assessed using the Visual Analog Scale (VAS) for pain, ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate worse pain. Scores will be recorded at multiple postoperative time points.

Time frame
multiple postoperative time points.
2

Total opioid consumption

Time frame
during the first 24 hours.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.